SI1202727T1 - - Google Patents

Info

Publication number
SI1202727T1
SI1202727T1 SI200030632T SI200030632T SI1202727T1 SI 1202727 T1 SI1202727 T1 SI 1202727T1 SI 200030632 T SI200030632 T SI 200030632T SI 200030632 T SI200030632 T SI 200030632T SI 1202727 T1 SI1202727 T1 SI 1202727T1
Authority
SI
Slovenia
Prior art keywords
nicotine
dependant
intend
agonists
subjects
Prior art date
Application number
SI200030632T
Other languages
English (en)
Inventor
Gian Luigi Gessa
Giancarlo Colombo
Luca Pani
Walter Fratta
Original Assignee
Molteni & C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molteni & C filed Critical Molteni & C
Publication of SI1202727T1 publication Critical patent/SI1202727T1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SI200030632T 1999-07-30 2000-06-30 SI1202727T1 (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT1999MI001715A IT1313585B1 (it) 1999-07-30 1999-07-30 Uso di agonisti dei recettori gabab per la terapia di mantenimentodell'astinenza da nicotina in soggetti nicotino-dipendenti.
PCT/EP2000/006120 WO2001008675A1 (en) 1999-07-30 2000-06-30 Use of agonists of gabab receptors and pharmaceutically acceptable derivates thereof, in the therapy of maintaining nicotine abstinence-dependent patients
EP00947901A EP1202727B1 (en) 1999-07-30 2000-06-30 Use of agonists of gabab receptors and pharmaceutically acceptable derivatives thereof, in the therapy of maintaining nicotine abstinence in nicotine-dependent patients

Publications (1)

Publication Number Publication Date
SI1202727T1 true SI1202727T1 (enExample) 2005-08-31

Family

ID=11383467

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200030632T SI1202727T1 (enExample) 1999-07-30 2000-06-30

Country Status (16)

Country Link
EP (1) EP1202727B1 (enExample)
CN (1) CN1176650C (enExample)
AT (1) ATE285763T1 (enExample)
AU (1) AU6153400A (enExample)
CA (1) CA2379752C (enExample)
DE (1) DE60017147T2 (enExample)
DK (1) DK1202727T3 (enExample)
ES (1) ES2235913T3 (enExample)
HK (1) HK1046849B (enExample)
IL (2) IL147876A0 (enExample)
IT (1) IT1313585B1 (enExample)
PL (1) PL196334B1 (enExample)
PT (1) PT1202727E (enExample)
RU (1) RU2262352C2 (enExample)
SI (1) SI1202727T1 (enExample)
WO (1) WO2001008675A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019163A2 (en) * 2003-08-20 2005-03-03 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
WO2006050471A2 (en) 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
WO2006050472A2 (en) 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
US7585996B2 (en) 2006-09-15 2009-09-08 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
JP4498407B2 (ja) 2006-12-22 2010-07-07 キヤノン株式会社 プロセスカートリッジ、電子写真画像形成装置、及び、電子写真感光体ドラムユニット
JP5291123B2 (ja) 2008-01-25 2013-09-18 ゼノポート,インコーポレイティド (3s)−アミノメチル−5−ヘキサン酸プロドラッグの結晶形態及びその使用
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
EP2250148B1 (en) 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
US7989641B2 (en) 2008-08-07 2011-08-02 Xenoport, Inc. Methods of synthesizing N-hydroxysuccinimidyl carbonates
WO2010017504A1 (en) 2008-08-07 2010-02-11 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
JP2012519212A (ja) 2009-03-03 2012-08-23 ゼノポート,インコーポレイティド R−バクロフェンプロドラッグの持効性放出経口投与形
US8344028B2 (en) 2009-04-17 2013-01-01 Xenoport, Inc. Gamma-amino-butyric acid derivatives as GABAB receptor ligands
WO2011081558A1 (ru) * 2009-08-21 2011-07-07 Komissarov Jury Vladimirovich Курительное устройство для отказа от табачного курения
US8580850B2 (en) 2011-08-11 2013-11-12 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use
WO2019195813A1 (en) * 2018-04-06 2019-10-10 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of substance use disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US5073539A (en) * 1990-01-22 1991-12-17 Ciba-Geigy Corporation Transdermal administration of zwitterionic drugs
US5760049A (en) * 1997-02-21 1998-06-02 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
RU2132203C1 (ru) * 1998-09-03 1999-06-27 Шакирзянов Галимзян Закирович Способ лечения табачной зависимости и антитабачный комбинированный препарат

Also Published As

Publication number Publication date
CA2379752C (en) 2008-05-27
DE60017147T2 (de) 2006-01-12
CN1377265A (zh) 2002-10-30
PT1202727E (pt) 2005-05-31
DK1202727T3 (da) 2005-05-09
EP1202727A1 (en) 2002-05-08
ATE285763T1 (de) 2005-01-15
ITMI991715A0 (it) 1999-07-30
HK1046849B (en) 2005-07-15
IL147876A0 (en) 2002-08-14
RU2262352C2 (ru) 2005-10-20
DE60017147D1 (de) 2005-02-03
CN1176650C (zh) 2004-11-24
HK1046849A1 (en) 2003-01-30
IT1313585B1 (it) 2002-09-09
EP1202727B1 (en) 2004-12-29
ITMI991715A1 (it) 2001-01-30
PL353373A1 (en) 2003-11-17
AU6153400A (en) 2001-02-19
WO2001008675A1 (en) 2001-02-08
CA2379752A1 (en) 2001-02-08
IL147876A (en) 2007-06-17
PL196334B1 (pl) 2007-12-31
ES2235913T3 (es) 2005-07-16

Similar Documents

Publication Publication Date Title
SI1202727T1 (enExample)
RU94040387A (ru) Композиция, способствующая прекращению курения, никотиносодержащий распыляемый раствор, способ снижения потребности в курении табака, способ замены курения табака
MY130619A (en) Pharmaceutical formulations of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene
MY123149A (en) Solid oral dosage forms of valsartan
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
NZ334270A (en) Glucagon like peptide (GLP-1), analogs and derivatives to treat post surgical catabolic changes and insulin resistance
ATE264102T1 (de) Nicotin enthaltende pharmazeutische zusammensetzungen mit schneller transmukosaler absorption
PL312219A1 (en) Application of nona- and decapeptides in obtaining a therapeutic agent for fighting against aids
MY127739A (en) Use of pramipexole for the treatment of addictive disorders
WO1999030718A3 (en) PROSTAGLANDIN E2/F2α COMBINATION FOR TREATING IMPOTENCE AND ENHANCING SEXUAL AROUSAL
EA200001049A1 (ru) Новые способы лечения нервных расстройств
IL136415A (en) Transmucosal formulations of levosimendan
AU9028098A (en) Combinations of endometrial sparing progestins and endometrial atrophizing progestins with estrogens, in oral contraception
PT1161254E (pt) Tratamento de doenças auto-imunes com extracto de ginseng americano
SE8801708D0 (sv) New use of dopamine receptor agonists
NZ337752A (en) Anhydrovinblastine for the treatment of cancers, including cervical and lung cancer
MY127600A (en) Solid oral dosage forms of valsartan